Wednesday, November 18, 2026 Vol. I · No. 6
Health · Via STAT

STAT+: FDA discloses reasons for rejecting Summit drug

Image: STAT

The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:

This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.

Read the full story at STAT ↗

statnews.com

More from the Health desk